Federal Funding for Fetal Tissue Research Ends

Hand pointing at stock chart on laptop screen — Photo: Chompoo Suriyo / Shutterstock

The National Institutes of Health (NIH) just shut off all federal money for research that uses tissue from aborted babies, ending a decades-old practice pro-life advocates have fought for years.

Story Snapshot

NIH issued a new policy notice banning funds for research using human fetal tissue from elective abortions, effective immediately.
The rule covers both NIH’s own internal research and all outside grants to universities and labs.
The move ends a funding practice that dates back to a 1993 Clinton-era policy reversal.
Congress has separate bills pending that would make the ban permanent law instead of agency policy.

NIH Cuts Off Funding for Fetal Tissue Studies

The National Institutes of Health announced this January that it will no longer pay for any research using human fetal tissue taken from elective abortions. The agency’s official notice states plainly that “NIH funds will not be permitted for research using HFT from elective abortions,” a rule that applies right away. Health and Human Services confirmed the ban in a formal statement, calling it a major policy shift.

NIH leaders framed the decision as part of a broader push to “modernize biomedical science and accelerate innovation,” according to the agency’s own release announcing the change. For pro-life Americans, the reasoning matters less than the result: taxpayer dollars can no longer flow to studies built on tissue harvested from babies killed in abortions, a practice many conservatives have called morally indefensible for decades.

Rule Reaches Every Corner of Federal Research

This is not a narrow fix limited to NIH’s own labs. The policy applies to “the NIH Intramural Research Program and all extramural research including competitive applications for grants and cooperative agreements,” meaning universities and outside researchers lose access to this funding too. That closes a loophole pro-life groups had long complained about, since past restrictions sometimes only touched internal government projects while outside grants kept flowing.

Health experts note the change follows years of decline in this kind of research anyway. One medical journal reported the administration justified the ban partly by pointing to a “sharp decline” in NIH-supported fetal tissue research since 2019, alongside a stated goal of redirecting resources elsewhere. Supporters see this as proof the door was already closing and the administration simply finished the job.

A Fight That Goes Back Nearly 40 Years

This battle did not start in 2026. In 1988, President Reagan’s Health and Human Services Department imposed the first moratorium on federal funding for fetal tissue transplant research, and that freeze held through the George H.W. Bush administration. President Clinton reversed course in 1993, signing a memorandum that reopened the door to NIH funding for this research, a decision that stood largely unchallenged for over 25 years.

The pendulum began swinging back during President Trump’s first term. In 2019, Health and Human Services announced it would end internal NIH fetal tissue projects following an audit, though outside grants were largely untouched at the time. Now, in his second term, President Trump’s administration has finished what that earlier move started, cutting off internal and external funding alike in one sweep.

Congress Wants the Ban Written Into Law

Pro-life lawmakers are not stopping at agency policy, which a future administration could reverse with the stroke of a pen. Senator Cindy Hyde-Smith, who chairs the Senate Pro-Life Caucus, reintroduced the Protecting Life and Integrity in Research Act to permanently bar every federal agency from funding, conducting, or approving research using fetal tissue from induced abortions. A companion bill in the House takes the same approach, seeking to ban the federal government from supporting any such research and from acquiring tissue in the first place.

Not everyone welcomes the change. One science journal argued the timing is wrong, warning the policy could slow research into serious diseases even though the agency will still allow tissue from miscarriages and stillbirths. Conservatives counter that ethical research boundaries matter more than convenience, and that plenty of alternatives exist that don’t rely on tissue from abortions.

For pro-life Americans who have pushed this issue since the Reagan years, the NIH’s move marks real progress. Turning it into permanent law remains the next fight, one that will test whether Congress can lock in what this administration has already delivered through policy.